The impact of the novel coronavirus disease (COVID-19) pandemic on drug overdose-related deaths in the United States and Canada: a systematic review of observational studies and analysis of public health surveillance data.
COVID-19
Canada
Death
Drug overdose
North America
SARS-CoV-2
United States
Journal
Substance abuse treatment, prevention, and policy
ISSN: 1747-597X
Titre abrégé: Subst Abuse Treat Prev Policy
Pays: England
ID NLM: 101258060
Informations de publication
Date de publication:
29 11 2021
29 11 2021
Historique:
accepted:
15
11
2021
entrez:
30
11
2021
pubmed:
1
12
2021
medline:
15
12
2021
Statut:
epublish
Résumé
There are preliminary indications that the trajectory of drug overdose-related deaths in North America has been exacerbated due to the novel coronavirus disease pandemic (COVID-19). As such, the impact of COVID-19 on drug overdose-related deaths was examined through a systematic review of the literature and percentage change analyses of surveillance data. Systematic searches in electronic databases were conducted, a topical issue brief and bibliography were reviewed, reference lists of included studies were searched and expert consultations were held to identify studies (Registration # CRD42021230223). Observational studies from the United States and Canada were eligible for inclusion if drug overdose-related deaths were assessed in quantitative or qualitative analyses onwards from at least March 2020. In addition, percentage changes comparing drug overdose-related deaths in the second annual quarter (Q2 2020 [April to June]) with the first annual quarter (Q1 2020 [January to March]) were generated using national and subnational data from public health surveillance systems and reports from jurisdictions in the United States and Canada. Nine studies were included in the systematic review, eight from the United States and one from Canada. The maximum outcome assessment period in the included studies extended until September 2020. Drug overdose-related deaths after the onset of COVID-19 were higher compared with the months leading up to the pandemic in 2020 and the comparative months in 2019. In additional percentage change analyses, drug overdose-related deaths increased by 2 to 60% in jurisdictions in the United States and by 58% in Canada when comparing Q2 2020 with Q1 2020. Drug overdose-related deaths increased after the onset of COVID-19. The current situation necessitates a multi-pronged approach, encompassing expanded access to substance use disorder treatment, undisrupted access to harm reduction services, emphasis on risk reduction strategies, provision of a safe drug supply and decriminalization of drug use.
Sections du résumé
BACKGROUND
There are preliminary indications that the trajectory of drug overdose-related deaths in North America has been exacerbated due to the novel coronavirus disease pandemic (COVID-19). As such, the impact of COVID-19 on drug overdose-related deaths was examined through a systematic review of the literature and percentage change analyses of surveillance data.
METHODS
Systematic searches in electronic databases were conducted, a topical issue brief and bibliography were reviewed, reference lists of included studies were searched and expert consultations were held to identify studies (Registration # CRD42021230223). Observational studies from the United States and Canada were eligible for inclusion if drug overdose-related deaths were assessed in quantitative or qualitative analyses onwards from at least March 2020. In addition, percentage changes comparing drug overdose-related deaths in the second annual quarter (Q2 2020 [April to June]) with the first annual quarter (Q1 2020 [January to March]) were generated using national and subnational data from public health surveillance systems and reports from jurisdictions in the United States and Canada.
RESULTS
Nine studies were included in the systematic review, eight from the United States and one from Canada. The maximum outcome assessment period in the included studies extended until September 2020. Drug overdose-related deaths after the onset of COVID-19 were higher compared with the months leading up to the pandemic in 2020 and the comparative months in 2019. In additional percentage change analyses, drug overdose-related deaths increased by 2 to 60% in jurisdictions in the United States and by 58% in Canada when comparing Q2 2020 with Q1 2020.
CONCLUSIONS
Drug overdose-related deaths increased after the onset of COVID-19. The current situation necessitates a multi-pronged approach, encompassing expanded access to substance use disorder treatment, undisrupted access to harm reduction services, emphasis on risk reduction strategies, provision of a safe drug supply and decriminalization of drug use.
Identifiants
pubmed: 34844624
doi: 10.1186/s13011-021-00423-5
pii: 10.1186/s13011-021-00423-5
pmc: PMC8628272
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
87Subventions
Organisme : CIHR Institute of Neurosciences, Mental Health and Addiction
ID : CUG-171602
Informations de copyright
© 2021. The Author(s).
Références
Harm Reduct J. 2021 Aug 5;18(1):85
pubmed: 34353323
Lancet Public Health. 2020 Apr;5(4):e186-e187
pubmed: 32171054
JAMA Psychiatry. 2021 Apr 1;78(4):372-379
pubmed: 33533876
Public Health. 2020 Jun;183:63
pubmed: 32405098
Epidemiol Rev. 2020 Jan 31;42(1):154-166
pubmed: 33511987
Digit Health. 2021 Jun 28;7:20552076211028404
pubmed: 34262782
J Subst Abuse Treat. 2021 Oct;129:108374
pubmed: 34080545
J Addict Med. 2020 Jul/Aug;14(4):e136-e138
pubmed: 32433364
Int J Drug Policy. 2020 Jun;80:102769
pubmed: 32446183
JAMA Netw Open. 2021 Jan 4;4(1):e2034878
pubmed: 33475751
Psychiatry Res. 2020 Jul;289:113096
pubmed: 32405115
Subst Abuse Treat Prev Policy. 2014 Oct 27;9:43
pubmed: 25352167
Int J Drug Policy. 2021 Jul;93:103237
pubmed: 33893026
CMAJ. 2020 May 11;192(19):E497-E505
pubmed: 32269018
Lancet. 2019 Oct 26;394(10208):1560-1579
pubmed: 31657732
Drug Alcohol Depend. 2014 Dec 1;145:48-68
pubmed: 25456324
J Stud Alcohol Drugs. 2020 Sep;81(5):556-560
pubmed: 33028465
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
JAMA Psychiatry. 2021 May 1;78(5):562-564
pubmed: 33270086
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
N Engl J Med. 2021 Jan 14;384(2):e6
pubmed: 33378604
Drug Alcohol Depend. 2020 Sep 1;214:108176
pubmed: 32717504
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Subst Abuse Treat Prev Policy. 2020 Aug 31;15(1):66
pubmed: 32867799
Mol Psychiatry. 2021 Jan;26(1):30-39
pubmed: 32929211
Int J Drug Policy. 2021 Jun;92:103127
pubmed: 33549464
Lancet Psychiatry. 2020 Jun;7(6):547-560
pubmed: 32304649
Addiction. 2021 Jan;116(1):6-17
pubmed: 32533570
J Urban Health. 2020 Dec;97(6):808-813
pubmed: 32989667
Lancet HIV. 2021 Jul;8(7):e387
pubmed: 34197768
J Urban Health. 2020 Dec;97(6):802-807
pubmed: 33005988
Lancet HIV. 2019 May;6(5):e269
pubmed: 31047667
Addiction. 2022 Mar;117(3):532-544
pubmed: 34729849
Subst Abuse Treat Prev Policy. 2021 Feb 15;16(1):17
pubmed: 33588896
J Subst Abuse Treat. 2021 May;124:108272
pubmed: 33771276